Pre-surgical weight loss in the surgical treatment of prostate cancer

Overweight and obese prostate cancer patients are often advised to lose weight prior to surgery for the treatment of localized forms of prostate cancer. But is this really, always, a good idea? … READ MORE …

Half of long-term erectile function (EF) loss after brachytherapy (BT) is due to aging

One of the most important things we patients want to know about any treatment is what kind of potency we can expect afterwards. Urinary and rectal dysfunctions are often measured and reported by investigators, but sexual dysfunction is rarely reported or measured. … READ MORE …

Cialis doesn’t help to maintain erectile function among radiotherapy patients

The degree to which drugs like sildenafil (Viagra) and taldalafil (Cialis) may help patient to maintain erectile function after treatment for localized prostate cancer has long been open to question. … READ MORE …

Degree of loss of muscle mass among men on long-term ADT

Unsurprisingly, according to a new article in the Journal of Clinical Oncology, long-term androgen deprivation therapy (ADT) is closely associated with loss of lean muscle mass (known as sarcopenia) in men being treated for prostate cancer. However, this appears to be the first time anyone has shown there is an age-related factor that is relevant to the degree of loss of lean muscle. … READ MORE …

ADT-associated weight change in the real world

Initiation of androgen deprivation therapy (ADT) has long been associated with the loss of lean muscle mass and a gain in mass of fatty tissue, leading toward an overall weight gain over time. However, data from the “real world” on the degree to which ADT actually affects body mass has been very limited. … READ MORE …

Risedronate prevents bone loss in patients on hormone therapy

A new study has shown that the generically available, oral, bisphosphonate risedronate (Actonel) can prevent bone loss and related effects in patients receiving hormonal therapy for prostate cancer. … READ MORE …